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Abstract
Background:  Despite improvements in the safety and efficacy of endovascular procedures,
considerable morbidity may still be attributed to vasospasm. Vasospasm has proven amenable to
pharmacological intervention such as nitrates, intravenous calcium channel blockers (CCBs), and
intra-arterial papaverine, particularly in small vessels. However, few studies have focused on
medium to large vessel spasm. Here we report the use of an intra-arterial CCB, verapamil, to treat
flow-limiting mechanically-induced spasm of the common carotid artery (CCA) in a primate. We
believe this to be the first such report of its kind.
Case presentation: As part of a study assessing the placement feasibility and safety of a catheter
capable of delivering intra-arterial cerebroprotective therapy, a female 16 kg baboon prophylaxed
with intravenous nitroglycerin underwent transfemoral CCA catheterization with a metallic 6-Fr
catheter without signs of acute spasm. The protocol dictated that the catheter remain in the CCA
for 12 hours. Upon completion of the protocol, arteriography revealed a marked decrease in CCA
size (mean cross-sectional area reduction = 31.6 ± 1.9%) localized along the catheter length. Intra-
arterial verapamil (2 mg/2cc) was injected and arteriography was performed 10 minutes later. Image
analysis at 6 points along the CCA revealed a 21.0 ± 1.7% mean increase in vessel diameter along
the length of the catheter corresponding to a 46.7 ± 4.0% mean increase in cross-sectional area.
Mean systemic blood pressure did not deviate more than 10 mm Hg during the procedure.
Conclusions:  Intraluminal CCBs like verapamil may constitute an effective endovascular
treatment for mechanically-induced vasospasm in medium to large-sized vessels such as the CCA.
Background
Rapid advancements in endovascular technology and
techniques allow for treatment of an ever-increasing range
of neurovascular diseases. Despite improvements in the
safety and efficacy of these procedures, complications
such as vasospasm, stroke, and perforation still occur [1].
Vasospasm, or contraction of smooth muscle fibers in the
wall of a vessel, is a commonly recognized adverse event
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that may complicate an endovascular procedure by limit-
ing distal blood flow.
Vasospasm complicates many disease states, particularly
those affecting small vessels. Recently, treatment of small-
vessel vasospasm has proven amenable to pharmacologi-
cal intervention. For example, in the treatment of cerebral
artery spasm, intravenous nitrates [2], intravenous cal-
cium channel blockers (CCBs) [3], and intra-arterial
papaverine [4] and CCBs [5] have been shown to prevent
or mitigate this small artery spasm. However, few studies
have focused on the treatment of medium and large vessel
spasm [6], and even fewer have taken aim at mechani-
cally-induced vasospasm. This type of spasm, unlike sub-
arachnoid hemorrhage-induced vasospasm, is not the
result of inflammation [7] and a functional nitric oxide
deficiency [8,9], but rather direct physical irritation of the
endothelium. In this report, we demonstrate the use of an
intra-arterial CCB, verapamil, to treat flow-limiting
mechanically-induced spasm of the common carotid
artery (CCA) in a non-human primate. We believe this to
be the first such report of its kind.
Case presentation
As part of a study aiming to assess the placement feasibil-
ity and safety of a catheter capable of delivering intra-arte-
rial cerebroprotective therapy, a 16 kg female baboon
(Papio anubis) underwent carotid artery catheterization
under general anesthesia. Since Papio anubis is regarded as
vasospasm-prone (unpublished data), the animal was
pre-treated with oral nimodipine (Nimotop, Bayer,1 mg/
kg every 4 hours for 24 hours), and placed on a prophy-
lactic infusion of intravenous nitroglycerin (200 mcg/hr)
and heparin (100 units/hr). To place a 6 Fr (2 mm) treat-
ment device in the 3–4 mm right CCA [10], the animal
underwent transfemoral catheterization with a 7 Fr guid-
ing catheter using Seldinger technique. Under single-
plane fluoroscopic guidance, the guiding catheter was
placed into the brachiocephalic artery (5–6 mm) and then
advanced into the right CCA after prophylactic adminis-
tration of 2 mg of intra-arterial verapamil (1 mg vera-
pamil/cc normal saline). A proprietary 6 Fr metallic
catheter was then passed through the guiding catheter.
Once inside the CCA, the 6 Fr catheter was exposed by
retraction of the 7 Fr guiding catheter. Control arteriogra-
phy, performed by injection of non-ionic iodinated con-
trast material through the guiding catheter, revealed
normal patency of the carotid artery without evidence of
spasm or limitation of arterial flow. As part of the study
protocol, this co-axial catheter system remained in the
brachiocephalic vessels for 12 hours. Throughout this pro-
cedure, the animal was maintained under general
anesthesia with a narcotic-nitrous mixture. Intravenous
nitroglycerin infusion (200 mcg/hr) and physiological
monitoring were continued. The guiding catheter was
connected to a heparinized saline infusion (3 units
heparin/cc normal saline at a rate of 30 cc/hour).
Before removing the co-axial system at the conclusion of
the experiment, carotid arteriography was performed to
verify positioning of the catheter and patency of the ves-
sels. These images revealed a decrease in vessel diameter
localized to the length of artery where the 6 Fr catheter was
positioned (Fig. 1A and 1C). Prior to further manipula-
tion of the catheters, an additional bolus of intra-arterial
verapamil (2 mg/ 2 cc normal saline) was instilled
through the guiding catheter positioned in the brachio-
cephalic artery. After ten minutes, repeat carotid arteriog-
raphy demonstrated a visible increase in vessel caliber,
presumably due to a reduction in vasospasm (Fig. 1B and
1D). The diameter of the CCA was compared before and
after verapamil administration at 6 equally-spaced points
along the catheter. This revealed an increase in the mean
CCA diameter from 2.85 ± 0.14 mm during spasm to 3.45
± 0.18 mm post-verapamil administration (Figure 2). This
corresponded to a 21.0 ± 1.7% mean increase in the vessel
diameter post-verapamil injection, which represents a
46.7 ± 4.0% mean increase in cross-sectional area (Fig. 3).
Review of continuous invasive blood pressure tracings
demonstrated minimal systemic response to the intra-
arterial administration of verapamil at this dosage; sys-
temic blood pressure did not deviate more than 10 mm
Hg systolic following instillation of verapamil.
At the conclusion of the procedure, the co-axial catheter
system was removed. Anesthetics, heparin, and nitroglyc-
erin infusions were discontinued. The animal was awak-
ened from anesthesia uneventfully showing no signs of
neurological impairment. MRI brain scan, including dif-
fusion-weighted imaging at 36 hours, showed no evi-
dence of cerebral infarction.
Discussion
Driven by technology and the ever-increasing need for
minimally invasive treatment modalities, the number of
endovascular procedures performed annually continues
to rise. The increased number and variety of endovascular
procedures have introduced new situations in which
vasospasm may be encountered. The sheer size and com-
plexity of large bore catheters and their delivery systems
makes them more likely to induce spasm in the vessel in
which they are utilized (medium and large caliber arter-
ies). Thus, it is important to identify pharmacological
agents that will relieve this vasospasm with minimal side
effects.
Spasm of arteries secondary to therapeutic medications or
diagnostic instrumentation has long been acknowledged
as a possible complication of interventional procedures.
Vasospasm, in general, has been attributed to a variety ofBMC Cardiovascular Disorders 2004, 4:11 http://www.biomedcentral.com/1471-2261/4/11
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pharmacological stimuli ranging from cocaine [11] and
alcohol [12], to L-thyroxine [13] and NSAIDs [14]. Vasos-
pasm may also be attributed to mechanical irritation [15],
as in the present study. In the past, treatment of mechan-
ical spasm has simply been withdrawal of the offending
catheter. A passive treatment such as this is often times
undesirable, especially when the catheter system needs to
remain in position, as in our experiment.
There are several agents that have been shown to be effec-
tive in preventing and treating vasospasm, each of which
has its limitations. Intravenous nitrates have been the
Anterior-posterior angiogram of right common carotid artery injection of a Papio anubis with a 6 Fr catheter in place both (A.)  during vessel spasm on catheter, and (B.) 10 minutes after infusion of intraluminal verapamil (2 mg) Figure 1
Anterior-posterior angiogram of right common carotid artery injection of a Papio anubis with a 6 Fr catheter in place both (A.) 
during vessel spasm on catheter, and (B.) 10 minutes after infusion of intraluminal verapamil (2 mg). Overlay images showing 6 
Fr catheter position in CCA (gold) during spasm (C.) and after alleviation with verapamil (D.). Arrows (→) indicate tip of 
catheter.
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mainstay of vasospasm prevention for endovascular
procedures [16], but their cardiovascular and intracranial
pressure (ICP) effects limit their acute use for vasospasm
treatment [17]. Intra-arterial papaverine has been used
either as monotherapy or as an adjunct to balloon angi-
oplasty in subarachnoid hemorrhage-induced vasospasm
of smaller cerebral vessels [4,18,19]. However, papaverine
therapy is short-acting, has untoward side-effects, such as
elevation of ICP, and its role in larger vessel spasm
remains ill-defined [20]. Recently, novel intra-arterial
agents, such as mannitol and amrinone, have been used
to reverse acute carotid spasm [21] and cerebral vasos-
pasm following subarachnoid hemorrhage [22], respec-
tively. Further efforts are needed to identify, compare, and
validate pharamacotherapies for medium to large vessel
spasm.
To reduce the tone of a muscular artery, a logical point of
intervention is inhibition of calcium influx into smooth
muscle cells. Voltage-sensitive CCBs, or 1, 4-dihydropyri-
dines (such as verapamil, nifedipine, nimodipine, and
amlodipine), function in this manner. Nimodipine
improves outcomes after cerebral vasospasm secondary to
subarachnoid hemorrhage [23]. Intraluminal
Image analysis at 6 paired positions (Lines A-F) along catheter in common carotid artery both (A.) during vessel spasm, and  (B.) 10 minutes after intraluminal verapamil (2 mg) administration Figure 2
Image analysis at 6 paired positions (Lines A-F) along catheter in common carotid artery both (A.) during vessel spasm, and 
(B.) 10 minutes after intraluminal verapamil (2 mg) administration. (C.) Raw data table includes vessel diameter measurements 
both pre and post-verapamil injection.
A B
A
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D
E
F
F
C Data Table 
Pre-Verapamil (A) Post-Verapamil (B)
Position Catheter
(mm)
Vessel
(mm)
 Position Catheter
(mm)
Vessel
(mm)
A 2  2.6 A 2  3.2
B 2  2.8 B 2  3.2
C 2  2.9 C 2  3.6
D 2  2.9 D 2  3.6
E 2  3.0 E 2  3.5
F 2  2.9 F 2  3.6
Mean 2.85  Mean 3.45 
 S.D. 0.14 S.D.  0.18 BMC Cardiovascular Disorders 2004, 4:11 http://www.biomedcentral.com/1471-2261/4/11
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administration of verapamil, in particular, has been used
for both the pretreatment of vessels for endovascular pro-
cedures [16], as well as reversal of spasm in coronary grafts
[6]. Recently, intra-arterial verapamil has also been
reported to be safe and effective in the treatment of cere-
bral vasospasm [5]. Verapamil is well tolerated systemi-
cally, yet hypotension is the primary concern during
administration.
In this case report we document the use of a 2 mg intra-
arterial verapamil injection into the CCA of a non-human
primate to acutely reverse catheter-induced vasospasm.
This use is unique for several reasons. Firstly, in contrast
to the report by He et al. [6], in which intra-arterial vera-
pamil was used to alleviate spasm of an internal thoracic
artery graft, we used verapamil to treat a significantly
larger caliber vessel. Secondly, the presence of elastic fib-
ers in the larger carotid artery compared to the highly
muscular internal thoracic artery represents a different
functional architecture. Thirdly, He et al. [6] attributed
their observed vasospasm to ionotrope therapy (dob-
utamine, dopamine, and epinephrine) that was instigated
for post-operative hemodynamic support. The spasm that
we observed, however, occurred in the presence of hemo-
dynamic stability and was isolated to a segment of the
carotid in close association with a metallic 6 Fr catheter,
suggesting mechanical irritation as the etiology.
This report serves as preliminary evidence for the utility of
intra-arterial verapamil in large vessel vasospasm and not
the conclusive study as its scope is limited by three issues.
First, by not having a control (untreated) subject, it is
impossible to say for sure that the observed mitigation of
vasospasm is due to the intervention and not the natural
history of the disease. Considering that effects were
observed in the presence of an in situ metallic catheter, we
believe strongly that the vasodilation was due to the vera-
pamil. Second, the observed mitigation of vasospasm
occurred during a continuous intravenous infusion of
nitrates. It is conceivable that the synergistic effects of ver-
apamil with these nitrates actually treated the vasospasm,
and not the verapamil itself. Finally, this study, by its
design, does not attempt to define the long-term durabil-
ity of intra-arterial verapamil. Only through additional
experimentation and use will the full utility of this agent
as an intraluminal treatment for vasospasm be
understood.
Conclusions
We describe the acute alleviation of in situ catheter-
induced CCA vasospasm in a non-human primate by an
intra-arterial infusion of verapamil (2 mg) without
demonstrable complications. Although only an observa-
tional study in one subject, this report suggests that intra-
arterial administration of verapamil may be an effective
intervention for the treatment of mechanically-induced
vasospasm in medium to large-sized muscular arteries
and that further experimentation in this area is warranted.
(A.) Bar graph depicting both the pre and post-verapamil mean vessel diameters from six positions along the length of the  common carotid artery (CCA) (2.85 ± 0.14 mm and 3.45 ± 0.18 mm, respectively), and (B.) cross-sectional areas (6.41 ± 0.61  mm2 and 9.39 ± 1.0 mm2, respectively) Figure 3
(A.) Bar graph depicting both the pre and post-verapamil mean vessel diameters from six positions along the length of the 
common carotid artery (CCA) (2.85 ± 0.14 mm and 3.45 ± 0.18 mm, respectively), and (B.) cross-sectional areas (6.41 ± 0.61 
mm2 and 9.39 ± 1.0 mm2, respectively). Note the 46.7% increase in mean cross-sectional area after verapamil administration.
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